Positive
●
CNBC
●
about 2 months ago
Eli Lilly reported second-quarter earnings and revenue that easily beat estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro surged again. The pharmaceutical giant now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of between $82 billion and $85 billion.